Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.
Also called NCT01605721
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,000 participants
- Registry
-
NCT01605721
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT01605721. Allocation not applicable; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)
- Condition
- Coronary Artery Disease
- Intervention (Device)
- XIENCE PRIMETM everolimus-eluting coronary stent
- Lead sponsor
- Seoul National University Hospital
- Collaborator
- Abbott
Record details
- Record id
cardio:ct-nct01605721- Content hash
873faa4e4705405de6aba3570f4b427f8dac182a018a1b9a58332b396ab41b69